

CONTACT - Media:

Amsterdam +31.20.721.4133
Dublin +353 1 617 4221
Oslo +47 22 34 17 40

Brussels +32.2.620.15.50
Lisbon +351.210.600.614
Paris +33.1.70.48.24.45

CONTACT - Investor Relations:

+33.1.70.48.24.17

HYLORIS PHARMACEUTICALS LISTS ON EURONEXT BRUSSELS

- **Initial market capitalisation of €253 million**
- **Strong support from the local retail investors (approx. 18.4% of the offered shares)**



Brussels, 29 June 2020 – Belgium-based biopharmaceutical company Hyloris Pharmaceuticals (ticker symbol: HYL) today began trading on Euronext Brussels (Compartment B). Through this IPO, Hyloris joins the franchise of 22 pharmaceutical companies currently listed on Euronext’s markets, representing a total market capitalisation of €143 billion (per 31 May 2020).

Based in Liège, Belgium, Hyloris is an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. By unlocking the untapped potentials of existing medications, Hyloris creates new and improved treatment options. Hyloris’ aim is to address the unmet medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system.

Hyloris Pharmaceuticals intends to use the proceeds of the IPO to fund the development of its existing portfolio of product candidates, the establishment a commercial team in the U.S. for Hyloris’ IV Cardiovascular Portfolio as well as the expansion of its product pipeline.

With an Offer Price at €10.75 per share, Hyloris’ total offering size amounts to €61.8 million, or €71 million, assuming the exercise in full of the Over-allotment Option. With a total of 23,551,768 shares admitted to trading, Hyloris has an initial market capitalisation of €253.2 million, or €262.45 million, assuming the exercise in full of the Over-allotment Option.

Stijn Van Rompay, Chief Executive Officer and co-founder of Hyloris, commented: “Our listing today and the funds raised will propel Hyloris to deliver significant value for all of its stakeholders including patients, physicians and payors in the healthcare system, as well as our shareholders and employees. I look forward to keeping the market updated on our progress.”

To mark Hyloris Pharmaceuticals' first trading day, Stijn Van Rompay, CEO of Hyloris, rang the opening bell in Brussels.



CONTACTS –

Euronext

Pascal Brabant (Brussels): +32 475 78 36 62; pbrabant@euronext.com

Hyloris Pharmaceuticals

Stijn Van Rompay, CEO +32 (0)4 346 02 07; investorrelations@hyloris.com

Consilium Strategic Communications +44 20 3709 5700; hyloris@consilium-comms.com

About Hyloris Pharmaceuticals SA

Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris' portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company's partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company's wider portfolio. Read more at www.hyloris.com. Hyloris stands for "high yield, lower risk" and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.

About Euronext

Euronext is the leading pan-European exchange, covering Belgium, France, Ireland, The Netherlands, Norway, Portugal and the UK. With close to 1,500 listed issuers worth €3.3 trillion in market capitalisation as of end March 2020, Euronext has an unmatched blue chip franchise that includes 25 issuers in the Morningstar® Eurozone 50 IndexSM, and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. The Norwegian stock exchange and its custody & settlement subsidiary, together operating as Oslo Børs VPS, joined Euronext on 17 June 2019.

For the latest news, find us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided “as is”, without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.

© 2020, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, “GDPR”), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: <https://www.euronext.com/en/privacy-policy>.

In accordance with the applicable legislation you have rights with regard to the processing of your personal data:

- for more information on your rights, please refer to: https://www.euronext.com/data_subjects_rights_request_information,
- to make a request regarding processing of your data or to unsubscribe to this press release service, please use our data subject request form at <https://connect2.euronext.com/form/data-subjects-rights-request> or email our Data Protection Officer at dpo@euronext.com.